Posted in:Regulatory Planned Clinical Trial for Aflibercept Signals Likely Future Contests Over Regeneron’s Eylea® By Spencer Johnson January 18, 2018 Comments are off On January 3, 2018, Momenta and Mylan announced their development plan for a proposed biosimilar to Regeneron’s Eylea® whose active... Read more Tagged with: aflibercept, Clinical trial, Eylea®, Formycon, Momenta Pharmaceuticals, Mylan, Regeneron http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus